4.33
18.63%
+0.68
Neurometrix Inc. stock is currently priced at $4.33, with a 24-hour trading volume of 254.35K.
It has seen a +18.63% increased in the last 24 hours and a +10.18% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.67 pivot point. If it approaches the $4.04 resistance level, significant changes may occur.
Neurometrix Inc. Stock (NURO) Financials Data
Neurometrix Inc. (NURO) Revenue 2024
NURO reported a revenue (TTM) of $5.90 million for the quarter ending December 31, 2023, a -28.52% decline year-over-year.
Neurometrix Inc. (NURO) Net Income 2024
NURO net income (TTM) was -$6.53 million for the quarter ending December 31, 2023, a -47.84% decrease year-over-year.
Neurometrix Inc. (NURO) Cash Flow 2024
NURO recorded a free cash flow (TTM) of -$6.27 million for the quarter ending December 31, 2023, a -17.99% decrease year-over-year.
Neurometrix Inc. (NURO) Earnings per Share 2024
NURO earnings per share (TTM) was -$5.8817 for the quarter ending December 31, 2023, a -16.91% decline year-over-year.
Neurometrix Inc. Stock (NURO) Latest News
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
GlobeNewswire Inc.
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
GlobeNewswire Inc.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
GlobeNewswire Inc.
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
GlobeNewswire Inc.
NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)
GlobeNewswire Inc.
NeuroMetrix Announces One-for-Eight Reverse Stock Split
GlobeNewswire Inc.
About Neurometrix Inc.
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Cap:
|
Volume (24h):